13.98
price down icon2.31%   -0.33
 
loading

Replimune Group Inc (REPL) 最新ニュース

pulisher
Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat

Feb 20, 2025
pulisher
Feb 18, 2025

Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com India

Feb 18, 2025
pulisher
Feb 17, 2025

Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St

Feb 17, 2025
pulisher
Feb 17, 2025

HC Wainwright Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World

Feb 17, 2025
pulisher
Feb 17, 2025

FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat

Feb 17, 2025
pulisher
Feb 14, 2025

Replimune stock target raised to $22 at H.C. Wainwright - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia

Feb 13, 2025
pulisher
Feb 12, 2025

Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha

Feb 12, 2025
pulisher
Feb 12, 2025

Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Group Inc. (REPL) reports earnings - Quartz

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Group, Inc. SEC 10-Q Report - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

FDA Fast-Tracks Replimune's Melanoma Treatment as Cash Reserves Hit $536M in Q3 Report - StockTitan

Feb 12, 2025
pulisher
Feb 10, 2025

Top Wealth Group Holding Ltd (TWG)’s financial ratios: A comprehensive overview - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Metric Analysis: Nvni Group Ltd (NVNI)’s Key Ratios in the Limelight - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Feb 10, 2025
pulisher
Feb 10, 2025

Replimune Group (REPL) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Feb 10, 2025
pulisher
Feb 08, 2025

How to Take Advantage of moves in (REPL) - Stock Traders Daily

Feb 08, 2025
pulisher
Feb 08, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 08, 2025
pulisher
Feb 07, 2025

Replimune's Strategic Move: $14.25 Stock Options Package Secures Top Talent - StockTitan

Feb 07, 2025
pulisher
Feb 07, 2025

Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World

Feb 07, 2025
pulisher
Feb 06, 2025

Holdings of Replimune Group Inc (REPL) are aligned with the stars - SETE News

Feb 06, 2025
pulisher
Feb 05, 2025

SG Americas Securities LLC Acquires 3,374 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Feb 05, 2025
pulisher
Feb 04, 2025

Was there any good news for Replimune Group Inc (REPL) stock in the last session? - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Upward Trajectory: Replimune Group Inc (REPL) Posts a Slidee, Closing at 13.71 - The Dwinnex

Feb 04, 2025
pulisher
Jan 31, 2025

Vanguard Group Inc's Strategic Acquisition of Replimune Group In - GuruFocus.com

Jan 31, 2025
pulisher
Jan 30, 2025

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital

Jan 30, 2025
pulisher
Jan 29, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Average Target Price from Analysts - Defense World

Jan 29, 2025
pulisher
Jan 26, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Consensus PT from Analysts - MarketBeat

Jan 26, 2025
pulisher
Jan 25, 2025

Replimune Group (NASDAQ:REPL) Stock Price Down 3.5%What's Next? - MarketBeat

Jan 25, 2025
pulisher
Jan 24, 2025

What is Wedbush’s Estimate for Replimune Group Q3 Earnings? - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

What is Wedbush's Estimate for Replimune Group Q3 Earnings? - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Replimune price target raised to $21 from $17 at H.C. Wainwright - Yahoo Finance

Jan 23, 2025
pulisher
Jan 23, 2025

Replimune Group (NASDAQ:REPL) Shares Up 6% After Analyst Upgrade - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Replimune announces priority review for its melanoma treatment - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

BMO Capital Markets Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - Yahoo Finance

Jan 22, 2025
pulisher
Jan 22, 2025

FDA accepts Replimune’s melanoma candidate for priority review - The Pharma Letter

Jan 22, 2025
pulisher
Jan 22, 2025

Replimune Group (NASDAQ:REPL) Price Target Raised to $21.00 at HC Wainwright - MarketBeat

Jan 22, 2025
pulisher
Jan 21, 2025

Replimune stock price target raised to $27 by BMO Capital - Investing.com Canada

Jan 21, 2025
pulisher
Jan 21, 2025

Replimune stock soars on FDA priority review for melanoma treatment - MSN

Jan 21, 2025
pulisher
Jan 21, 2025

Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com Canada

Jan 21, 2025
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):